$-0.03
(Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$-2 Mln
P/E Ratio
--
P/B Ratio
122.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-5 Mln
ROE
-7.2 %
ROCE
-- %
Industry P/E
46.76
EV/EBITDA
-6.6
Debt to Equity
-1.7
Book Value
$--
EPS
$-0.4
Face value
--
Shares outstanding
40,351,702
CFO
$-32.43 Mln
EBITDA
$-35.99 Mln
Net Profit
$-60.68 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nemaura Medical (NMRD)
| -- | -- | -- | -- | -95.2 | -88.6 | -69.6 |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Nemaura Medical (NMRD)
| -87.2 | -62.3 | 21.0 | 7.7 | -61.1 | -82.2 | 237.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nemaura Medical (NMRD)
|
0.0 | 0.0 | -1.6 | -10.7 | 377.7 | -- | -- | 122.6 |
| 7.9 | 5,292.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 299.5 | 8,082.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10.8 | 1.1 | |
| 36.6 | 5,563.8 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.2 | |
| 121.5 | 7,074.2 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.8 | |
| 84.3 | 5,490.1 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.7 | 5.0 | |
| 178.6 | 9,353.6 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.8 | 13.0 | |
| 329.9 | 13,067.9 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73.7 | 9.1 | |
| 117.6 | 6,632.6 | 738.3 | 48.9 | 11.4 | 2.4 | 136.7 | 3.2 | |
| 31.6 | 13,623.0 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.3 | 2.6 |
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes,... as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. Read more
Chairman, Interim CFO, CEO, President and Principal Financial & Accounting Officer
Dr. Dewan Fazlul Hoque Chowdhury Ph.D.
Chairman, Interim CFO, CEO, President and Principal Financial & Accounting Officer
Dr. Dewan Fazlul Hoque Chowdhury Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Nemaura Medical Inc (NMRD) is $0.00 (NASDAQ) as of 24-Apr-2026 09:30 EDT. Nemaura Medical Inc (NMRD) has given a return of -95.16% in the last 3 years.
Since, TTM earnings of Nemaura Medical Inc (NMRD) is negative, P/E ratio is not available.
The P/B ratio of Nemaura Medical Inc (NMRD) is 122.56 times as on 24-Apr-2026, a 3683 premium to its peers’ median range of 3.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-1.83
|
-2.19
|
|
2022
|
-7.34
|
218.59
|
|
2021
|
-27.98
|
20.95
|
|
2020
|
-29.41
|
-93.19
|
|
2019
|
-4.81
|
9.61
|
The 52-week high and low of Nemaura Medical Inc (NMRD) are Rs 0.00 and Rs 0.00 as of 27-Apr-2026.
Nemaura Medical Inc (NMRD) has a market capitalisation of $ 0 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Nemaura Medical Inc (NMRD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.